Biogen Idec, Orphan Biovitrum partner for hemophilia B drug trial

Biogen Idec is collaborating with Orphan Biovitrum on a clinical trial to evaluate the safety and efficacy of a recombinant Factor IX Fc fusion protein in preventing bleeding in hemophilia B patients. Biogen Idec also received FDA approval to market Ampyra, a multiple sclerosis drug it owns with Acorda Therapeutics.

View Full Article in:

Mass High Tech (Boston) · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations